HM
ZURA icon

Howard Marks’s Zura Bio ZURA Stock Holding History

Howard Marks’s Portfolio ZURA Stock Details ZURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-150,000
Closed -$1.47M – 381
2021
Q3 		$1.47M Buy
+150,000
New +$1.47M 0.02% 223

Other funds holding ZURA

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $469M AUM 32.23% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Howard Marks's ZURA Position: Q4 2021 in Review

Howard Marks sold out of Zura Bio (ZURA) in Q4 2021, closing a stake of 150,000 shares — an estimated $1.47M sold.

Howard Marks first reported a position in ZURA in Q3 2021 and held it in 1 quarter. The position peaked at $1.47M in Q3 2021. 25 funds tracked by Wall St. Rank hold ZURA as of Q4 2021.

  • Howard Marks reported no remaining Zura Bio position as of Q4 2021 after selling out during the quarter.
  • Howard Marks sold 150,000 Zura Bio shares in Q4 2021, an estimated $1.47M.
  • Howard Marks first reported a position in Zura Bio in Q3 2021 and held it in 1 quarter.
  • Howard Marks's Zura Bio position peaked at $1.47M in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Zura Bio as of Q4 2021.

Based on Oaktree Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.